239 related articles for article (PubMed ID: 36602797)
1. Analysis of a Sabin-Strain Inactivated Poliovirus Vaccine Response to a Circulating Type 2 Vaccine-Derived Poliovirus Event in Sichuan Province, China 2019-2021.
Yang H; Qi Q; Zhang Y; Wen N; Cao L; Liu Y; Fan C; Yan D; Zhu X; Hao L; Zhu S; Ma Q; Liu J; Ma C; Nan L; Chen Y; Ma X; Chen N; Deng K; Shao G; Ding X; An Z; Rodewald LE; Li X; Wang D; Zhu H; Wang H; Feng Z; Xu W; Zhou J; Yin Z;
JAMA Netw Open; 2023 Jan; 6(1):e2249710. PubMed ID: 36602797
[TBL] [Abstract][Full Text] [Related]
2. Strategic Response to an Outbreak of Circulating Vaccine-Derived Poliovirus Type 2 - Syria, 2017-2018.
Mbaeyi C; Wadood ZM; Moran T; ; Ather F; Stehling-Ariza T; Nikulin J; Al Safadi M; Iber J; Zomahoun L; Abourshaid N; Pang H; Collins N; Asghar H; Butt OUI; Burns CC; Ehrhardt D; Sharaf M
MMWR Morb Mortal Wkly Rep; 2018 Jun; 67(24):690-694. PubMed ID: 29927908
[TBL] [Abstract][Full Text] [Related]
3. Type 2 Poliovirus Detection after Global Withdrawal of Trivalent Oral Vaccine.
Blake IM; Pons-Salort M; Molodecky NA; Diop OM; Chenoweth P; Bandyopadhyay AS; Zaffran M; Sutter RW; Grassly NC
N Engl J Med; 2018 Aug; 379(9):834-845. PubMed ID: 30157398
[TBL] [Abstract][Full Text] [Related]
4. Vaccine-derived poliovirus serotype 2 outbreaks and response in the Democratic Republic of the Congo, 2017-2021.
Alleman MM; Jorba J; Riziki Y; Henderson E; Mwehu A; Seakamela L; Howard W; Kadiobo Mbule A; Nsamba RN; Djawe K; Yapi MD; Mengouo MN; Gumede N; Ndoutabe M; Kfutwah AKW; Senouci K; Burns CC
Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A35-A47. PubMed ID: 36907733
[TBL] [Abstract][Full Text] [Related]
5. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.
Ciapponi A; Bardach A; Rey Ares L; Glujovsky D; Cafferata ML; Cesaroni S; Bhatti A
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011260. PubMed ID: 31801180
[TBL] [Abstract][Full Text] [Related]
6. Vaccine-derived poliovirus surveillance in China during 2001-2013: the potential challenge for maintaining polio free status.
Wang HB; Luo HM; Li L; Fan CX; Hao LX; Ma C; Su QR; Yang H; Reilly KH; Wang HQ; Wen N
BMC Infect Dis; 2017 Dec; 17(1):742. PubMed ID: 29197328
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for the spread of vaccine-derived type 2 polioviruses after global withdrawal of trivalent oral poliovirus vaccine and the effects of outbreak responses with monovalent vaccine: a retrospective analysis of surveillance data for 51 countries in Africa.
Cooper LV; Bandyopadhyay AS; Gumede N; Mach O; Mkanda P; Ndoutabé M; Okiror SO; Ramirez-Gonzalez A; Touray K; Wanyoike S; Grassly NC; Blake IM
Lancet Infect Dis; 2022 Feb; 22(2):284-294. PubMed ID: 34648733
[TBL] [Abstract][Full Text] [Related]
8. Environmental Surveillance Complements Case-Based Surveillance of Acute Flaccid Paralysis in Polio Endgame Strategy 2019-2023.
Chen P; Liu Y; Wang H; Liu G; Lin X; Zhang W; Ji F; Xu Q; Tao Z; Xu A
Appl Environ Microbiol; 2020 Jul; 86(15):. PubMed ID: 32444474
[TBL] [Abstract][Full Text] [Related]
9. Introduction of inactivated poliovirus vaccine leading into the polio eradication endgame strategic plan; Hangzhou, China, 2010-2014.
Liu Y; Wang J; Liu S; Du J; Wang L; Gu W; Xu Y; Zuo S; Xu E; An Z
Vaccine; 2017 Mar; 35(9):1281-1286. PubMed ID: 28161421
[TBL] [Abstract][Full Text] [Related]
10. Detection and Initial Response to a Type 2 Vaccine-Derived Poliovirus - Sichuan Province, China, 2019.
Zhou J; Wen N; Zhang Y; Qi Q; Fan C; Yan D; Zhu X; Hao L; Zhu S; Liu Y; Ma X; Ma C; Nan L; Chen Y; Ma Q; Wang C; Deng K; Cao L; Shao G; Ding X; Yang H; An Z; Rodewald LE; Xu A; Wang H; Feng Z; Yin Z; Wu X; Xu W
China CDC Wkly; 2020 Mar; 2(11):172-175. PubMed ID: 34594618
[TBL] [Abstract][Full Text] [Related]
11. Dynamic changes in polioviruses identified by environmental surveillance in Guangzhou, 2009-2021.
Chen M; Zhang Y; Zhang W; Huang S; Zhu S; Li C; Guo X; Zeng H; Fang L; Ke B; Li H; Yoshida H; Xu W; Ke C; Deng X; Zheng H
J Med Virol; 2023 Mar; 95(3):e28668. PubMed ID: 36905116
[TBL] [Abstract][Full Text] [Related]
12. Metagenomic sequencing, molecular characterization, and Bayesian phylogenetics of imported type 2 vaccine-derived poliovirus, Spain, 2021.
Fernandez-Garcia MD; Faye M; Diez-Fuertes F; Moreno-Docón A; Chirlaque-López MD; Faye O; Cabrerizo M
Front Cell Infect Microbiol; 2023; 13():1168355. PubMed ID: 37201115
[TBL] [Abstract][Full Text] [Related]
13. [Discovery of Foci of Type-2 Poliovirus Derived from Oral Polio Vaccine in Central African Republic in 2019].
Kalthan E; Gouandjika-Vasilache I; Mbailao R; Doté JW; Kossone MN; Gbangai M
Med Trop Sante Int; 2021 Jun; 1(2):. PubMed ID: 35586583
[TBL] [Abstract][Full Text] [Related]
14. Epidemiological survey and genetic characterization of type 3 vaccine-derived poliovirus isolated from a patient with four doses of inactivated polio vaccine in Henan Province, China.
Zhang M; Yang J; Bai Y; Zhu H; Wang C; Zhang L; Xu J; Lu M; Zhang X; Xiao Z; Ma Y; Wang Y; Li X; Wang D; Zhu S; Yan D; Xu W; Zhang Y; Zhang Y
Infect Dis Poverty; 2022 Dec; 11(1):124. PubMed ID: 36514167
[TBL] [Abstract][Full Text] [Related]
15. Surveillance of immunity acquired from poliovirus immunization including vaccination with the Sabin strain-derived inactivated vaccine.
Hotta C; Ogawa T; Shirasawa H
Hum Vaccin Immunother; 2019; 15(5):1154-1159. PubMed ID: 30676843
[TBL] [Abstract][Full Text] [Related]
16. Sporadic isolation of sabin-like polioviruses and high-level detection of non-polio enteroviruses during sewage surveillance in seven Italian cities, after several years of inactivated poliovirus vaccination.
Battistone A; Buttinelli G; Fiore S; Amato C; Bonomo P; Patti AM; Vulcano A; Barbi M; Binda S; Pellegrinelli L; Tanzi ML; Affanni P; Castiglia P; Germinario C; Mercurio P; Cicala A; Triassi M; Pennino F; Fiore L
Appl Environ Microbiol; 2014 Aug; 80(15):4491-501. PubMed ID: 24814793
[TBL] [Abstract][Full Text] [Related]
17. Monovalent type 2 OPV (mOPV2) management in the field: Interventions and lessons learned.
Afsar A; Mallya A; Mohammed AAG; Anand S; Diomande VKF; Maufras du Châtellier G; Ather F
Vaccine; 2023 Apr; 41 Suppl 1():A79-A84. PubMed ID: 36642630
[TBL] [Abstract][Full Text] [Related]
18. Sabin polio virus protein 1 (VP1) evolution in patients with acute flaccid paralysis from 2010 to 2016 in Uganda.
Nanteza MB; Bakamutumaho B; Tushabe P; Namuwulya P; Birungi M; Dhatemwa R; Eliku JP; Tibanagwa M; Kakooza P; Bukenya H; Bwogi J; Byabamazima CR
Virol J; 2023 Aug; 20(1):172. PubMed ID: 37533043
[TBL] [Abstract][Full Text] [Related]
19. [Circulating vaccine-derived poliovirus type 2 outbreak in Democratic Republic of Congo 2011-2012].
Bazira L; Coulibaly T; Mayenga M; Ncharre C; Yogolelo R; Mbule A; Moudzeo H; Lwamba P; Mulumba AW; Cabore J
Bull Soc Pathol Exot; 2015 Oct; 108(4):235-41. PubMed ID: 26288132
[TBL] [Abstract][Full Text] [Related]
20. An outbreak of type π vaccine-derived poliovirus in Sichuan province, China: emergence and circulation in an under-immunized population.
Wang HB; Fang G; Yu WZ; Du F; Fan CX; Liu QL; Hao LX; Liu Y; Zheng JS; Qin ZY; Xia W; Zhang SY; Yin ZD; Jing Q; Zhang YX; Huang RN; Yang RP; Tong WB; Qi Q; Guan XJ; Jing YL; Ma QL; Wang J; Ma XZ; Chen N; Zheng HR; Li YQ; Ma C; Su QR; Reilly KH; Luo HM; Wu XP; Wen N; Yang WZ
PLoS One; 2014; 9(12):e113880. PubMed ID: 25503964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
